We gleaned this information from our observations today when Benzinga's options scanner highlighted 11 extraordinary options ...
A patient has died while taking a closely watched gene therapy for muscular dystrophy. Sarepta Therapeutics announced the ...
The death of a 16-year-old boy evokes a lengthy battle to realize the benefit of cutting-edge gene therapy while also ...
Shares of Sarepta Therapeutics have struggled for the past year due to concerns about the commercial potential of its gene ...
Sarepta stock may recover sharply as additional information and data reveal that the adverse event reported by the company is ...
2d
HealthDay on MSNSarepta’s Gene Therapy Under Scrutiny After Patient DeathA patient has died while receiving Elevidys, a gene therapy for Duchenne muscular dystrophy, marking the first known death ...
Elevidys was approved after intense debate at the FDA, as officials and reviewers disagreed over how strong the evidence was ...
In a report released yesterday, Gavin Clark-Gartner from Evercore ISI maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report), ...
StockStory.org on MSN4d
Why Sarepta Therapeutics (SRPT) Shares Are Sliding TodayShares of biotech company Sarepta Therapeutics (NASDAQ:SRPT) fell 24.9% in the pre-market session after the company reported ...
2d
Zacks Investment Research on MSNStrength Seen in Sarepta Therapeutics (SRPT): Can Its 8.7% Jump Turn into More Strength?Sarepta Therapeutics SRPT shares soared 8.7% in the last trading session to close at $79.97. The move was backed by solid volume with far more shares changing hands than in a normal session. This ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results